1-Substituted Indazole Derivative Modulating Alpha7 nAChR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modulators of the α7 nicotinic acetylcholine receptor (α7 nAChR) lack potent and novel compounds effective for treating nervous system diseases, psychiatric diseases, and inflammatory diseases.
Innovation Solution
A novel 1-substituted indazole derivative, as defined by Formula (I), which acts as a potent modulator of the α7 nicotinic acetylcholine receptor, offering a new pharmacological approach for treating and preventing these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing modulators of α7 nAChR are used, then some therapeutic effects can be achieved, but the compounds lack sufficient potency and novelty for effectively treating nervous system diseases, psychiatric diseases, and inflammatory diseases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of indazole derivatives, specifically at the 1-position substitution and surrounding groups (R1A-R1E, R2A-R2E, X-Y-Z moieties). These structural parameter changes result in compounds with enhanced potency and selectivity for α7 nAChR, directly addressing the need for more effective modulators while maintaining the core pharmacological activity
Solution Approach 2:
The invention creates composite molecular structures by combining the indazole core with various substituent groups (amino groups, carbonyl groups, cyclic structures) to form complex hybrid molecules. This composite approach allows optimization of both potency and therapeutic profile, producing novel compounds that overcome the limitations of existing single-structure modulators
2Adaptability or versatility
If a novel compound structure is developed, then new therapeutic options are provided, but the compound must still achieve potent modulatory effects on α7 nAChR activity
Solution Approach 1:
The patent systematically varies chemical parameters including the type of substituent at position 1 (amino groups, carbonyl groups), the nature of R1A-R1E and R2A-R2E groups (alkyl, alkoxy, halogen, cycloalkyl), and the X-Y-Z moiety structure. These controlled parameter changes generate novel compounds while preserving and enhancing α7 nAChR modulatory potency through structure-activity relationship optimization
Solution Approach 2:
The invention applies local quality by making specific modifications to particular regions of the indazole molecule (1-position substitution, 3-5 position substituents) while maintaining the integrity of the core structure. This localized optimization allows the compound to achieve both novelty and potent local interaction with the α7 nAChR binding site
Data Source
AI summary
A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I):wherein A is CR1E or a nitrogen atom, X—Y—Z is N—CO—NR3AR3B and the like, R1A to R1E are each independently a hydrogen atom and the like, R2A to R2D are each independently a hydrogen atom and the like, R3A and R3B are each independently an optionally-substituted C3-10 cycloalkyl and the like, and n is 1 or 2or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of α7 nicotinic acetylcholine receptor (α7 nAChR).